ESR1 and breast cancer: Adjuvant tamoxifen (given for 5 years) showed a 31% decrease in mortality rate from BC in patients with estrogen receptor (ER)-positive BC and proved to be superior to 1 or 2 years of tamoxifen treatment (102).